ADMS stock news

The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences … Read more
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 9) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed Oct. 3) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 9) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Albireo Pharma Inc (NASDAQ: ALBO ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Assembly Biosciences Inc (NASDAQ: ASMB ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BioNano Genomics Inc (NASDAQ: BNGO ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Caladrius Biosciences Inc (NASDAQ: CLBS ) Calithera Biosciences Inc (NASDAQ: CALA ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Erytech Pharma SA (NASDAQ: ERYP ) Exagen Inc (NASDAQ: XGN ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gossamer Bio Inc (NASDAQ: GOSS ) Heat Biologics Inc (NASDAQ: HTBX ) Homology Medicines Inc (NASDAQ: FIXX ) INmune Bio Inc (NASDAQ: INMB ) Intellia Therapeutics Inc (NASDAQ: … Read more
The following is a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE or Nasdaq-listed biotech stocks hit 52-week highs on Tuesday. Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 8.) ABIOMED, Inc. (NASDAQ: ABMD ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Albireo Pharma Inc (NASDAQ: ALBO ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) BIOLASE Inc (NASDAQ: BIOL ) BioTelemetry Inc (NASDAQ: BEAT ) CELYAD SA/ADR (NASDAQ: CYAD ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Clovis Oncology Inc (NASDAQ: CLVS ) (Goldman reiterated a Sell rating on the stock and cut the price target from $13 to $3.) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) CytomX Therapeutics Inc (NASDAQ: CTMX ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Endologix, Inc. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week lows on Oct. 3) Aprea Therapeutics Inc (NASDAQ: APRE ) (IPOed on Thursday) Viela Bio Incn (NASDAQ: VIE ) (IPOed on Thursday) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 3) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) bluebird bio Inc . (NASDAQ: BLUE ) Corvus Pharmaceuticals Inc (NASDAQ: CRVS ) DelMar Pharmaceuticals Inc (NASDAQ: DMP ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Erytech Pharma SA (NASDAQ: ERYP ) Frequency Therapeutics Inc (NASDAQ: FREQ )(IPOed on Thursday) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Jaguar Health Inc (NASDAQ: JAGX ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Neuralstem, Inc. (NASDAQ: CUR ) Obseva SA (NASDAQ: OBSV ) Onconova Therapeutics Inc (NASDAQ: ONTX ) RA Medical Systems Inc (NYSE: RMED ) Sierra Oncology Inc (NASDAQ: SRRA ) Titan Pharmaceuticals, Inc. (NASDAQ: TTNP ) Trinity Biotech plc (NASDAQ: TRIB ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Arbutus Halts Hepatitis B Drug Study Arbutus Biopharma Corp (NASDAQ: ABUS ) decided to discontinue the development of AB-506, an oral capsid inhibitor, which was being evaluated in a Phase 1a/1b trial for the treatment … Read more
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
As of late, it has definitely been a great time to be an investor Adamas Pharmaceuticals. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) Cardiovascular Systems Inc (NASDAQ: CSII ) Cortexyme Inc (NASDAQ: CRTX ) EXACT Sciences Corporation (NASDAQ: EXAS ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Merck & Co., Inc. (NYSE: MRK ) ( Keytruda received one more approval, this time for metastatic small cell lung cancer in patients who have been treated previously) Novocure Ltd (NASDAQ: NVCR ) Repligen Corporation (NASDAQ: RGEN ) SAGE Therapeutics Inc (NASDAQ: SAGE ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Zynex Inc. (NASDAQ: ZYXI ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 18) Abeona Therapeutics Inc (NASDAQ: ABEO ) BioNano Genomics Inc (NASDAQ: BNGO ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kezar Life Sciences Inc (NASDAQ: KZ ) Mediwound Ltd (NASDAQ: MDWD ) MEREO BIOPHARMA/ADR (NASDAQ: MREO ) Trinity Biotech plc (NASDAQ: TRIB ) Stocks In Focus Adamas Parkinson's Drug Reduces Frequency And Duration of Daily Episodes of Dyskinesia and OFF Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) announced retrospective data analysis from pooled Phase 3 study of its Gocovri extended release capsules, which showed that the drug reduced both the number and duration of troublesome dyskinesia and OFF episodes relative to placebo such that patients experienced approximately half as many … Read more

What Makes Adamas (ADMS) a New Buy Stock

01:00pm, Tuesday, 18'th Jun 2019
Adamas (ADMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system. Read more

New commercial chief at Adamas Pharma

08:48pm, Thursday, 30'th May 2019
Read more

Adamas (ADMS) Upgraded to Buy: Here's Why

01:00pm, Tuesday, 14'th May 2019
Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). Read more
Adamas (ADMS) delivered earnings and revenue surprises of 4.42% and -8.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more

Proudly made at

ROCKIT